The World Bank has approved $10. 1 billion in immunization assistance operations in 78 countries, broken down as follows: IBRD $4. 94 billion, IDA $4. 91 billion, other budget of $240 million (including co-financing funds, special financing, and the Global Fund). ). funds). For a full list of projects by country or region, please visit our Projects & Operations website.
Africa: Angola has turned the challenge of COVID-19 into a development opportunity, embarking on a virtual transformation that puts the individual at the centre of the chain. Learn more
East Asia and the Pacific: Strong partnerships and flexible financial approaches have helped countries improve their immunization systems while making investments in health, education, and social coverage to ensure a more resilient future. Learn more
More on COVID-19 outcomes
More in-depth articles on COVID-19
The World Bank temporarily mobilized vaccine financing to facilitate the procurement and distribution of vaccines at an affordable and equitable cost, and to communicate to potential suppliers that the Bank’s financing would reach their consumers. Such a commitment would incentivize vaccine brands to supply vaccines to emerging economies at affordable prices. All of the Bank’s eligible consumer countries (IBRD/IDA) had the opportunity to access vaccine financing under their existing IDA loan packages and IBRD exposure limits. The World Bank Group has been building solidarity with COVAX, WHO, UNICEF, and other partners at the global and country levels with IDA and IBRD countries. This investment can only be used across countries to pay bills to COVAX, which included the procurement of additional doses beyond the 20% supplied through COVAX, in which countries aim for higher degrees of coverage.
IFC’s $4 billion Global Health Platform has helped personal corporations offer fitness products and services, including vaccines, to emerging countries. This included investments in vaccine brands for increased production of COVID-19 vaccines in low- and middle-income countries, with production allocated to emerging markets. There was also an opportunity to invest in production to address other potential bottlenecks, adding vials, needles and syringes, as well as bloodless garage capacity. Support was provided to map COVID-19 vaccine production capacities.
This builds on the World Bank Group’s experience in supporting large-scale immunization systems that oppose vaccine-preventable diseases, as well as public fitness systems to combat infectious diseases such as HIV, tuberculosis, malaria, and overlooked tropical diseases.
Readiness Assessment:
The Bank worked with partners to assess the readiness of countries’ systems for vaccine rollouts and identify gaps and potential spaces for investment. This has enabled the Bank to respond to countries’ priority wishes. These tests included an investigation of policies and regulations. skills, knowledge and tracking systems, fitness infrastructure adding bloodless chains, and education of fitness workers. Assessments had already been carried out in more than 140 countries.
Vaccine Eligibility:
As eligibility criteria for IBRD/IDA resources for vaccine procurement, the Bank had accepted (i) a normal or emergency license or authorization of at least one of the known RASs through WHO for vaccines procured and/or provided under the COVAX Fund, as would possibly be amended from time to time through WHO; or (ii) WHO Prequalification (PQ) or WHO Emergency Use Listing (EUL).
Vaccine Procurement:
Vaccine Distribution:
To help countries prepare for the rollout of vaccines and their fitness systems, Bank financing has been used to formulate safe and effective implementation policies, build stockpiles and expand bloodless chains, identify knowledge and monitoring systems, exercise fitness workers, and build confidence in immunization through citizen and network participation.